Notably, our own unpublished data from our early, ACPA positive, inception RA cohort study’s bulk RNAseq CTAP prediction analyses further support this dynamic shift in pathotypes post-treatment. The gene discussed is PRTN3; the disease is rheumatoid arthritis.